P

Pfizer

Makes cancer drugs, vaccines and other medicines

Regulatory Affairs Associate / Senior Associate

Full-TimeDeadline 11/30/26
No salary listed
Junior, Mid
Bachelor's
Makati, Metro Manila, Philippines
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A bachelor's degree or equivalent in Pharmacy, Life Sciences, Business, or Information Technology is required.
  • At least 2 years of experience for Associate and 3 or more years for Senior Associate are required.
  • Fluent English is required.
  • Proven technical aptitude and the ability to quickly learn and use new software, regulations, and quality standards are required.
  • Advanced Microsoft Office Suite skills are required.
  • Associate-level candidates should demonstrate foundational regulatory operations knowledge and technical expertise for assigned regulatory submission and lifecycle management activities.
  • Associate-level candidates should be able to work under guidance and management oversight while building independence and technical proficiency.
  • Associate-level candidates should quickly learn and apply regulatory processes, systems, tools, and procedures to deliver high-quality work within established timelines and compliance requirements.
  • Associate-level candidates should communicate clearly and effectively, verbally and in writing, and deliver presentations mainly to internal teams.
  • Associate-level candidates should contribute to project and team deliverables through collaboration, attention to detail, and execution of assigned responsibilities.
  • Associate-level candidates should adapt to a dynamic regulatory environment while balancing quality, compliance, and business priorities.
  • Associate-level candidates should maintain a commitment to compliance, quality, continuous learning, and operational excellence.
  • Associate-level candidates should use approved artificial intelligence-enabled tools to improve productivity, learning, document drafting, information analysis, and daily work, applying appropriate judgment and responsible artificial intelligence practices.
  • Senior Associate candidates should demonstrate advanced regulatory operations and submission management expertise to support lower- to medium-complexity regulatory activities and submissions.
  • Senior Associate candidates should independently identify, analyze, and resolve moderately complex issues, navigate ambiguity, and determine when escalation or broader stakeholder engagement is needed.
  • Senior Associate candidates should be proficient in regulatory systems, workflows, and document management tools, and quickly learn and apply new technologies, processes, and standards.
  • Senior Associate candidates should plan, prioritize, and manage multiple projects and competing deadlines while maintaining quality, compliance, and customer focus.
  • Senior Associate candidates should communicate complex information clearly to diverse stakeholders through verbal and written communication, presentations to local, regional, and global teams, and customer engagement.
  • Senior Associate candidates should demonstrate adaptability and resilience in a dynamic, fast-paced environment, embrace change, and identify opportunities for innovation and continuous improvement.
  • Senior Associate candidates should work independently under general supervision and take ownership of deliverables, priorities, and outcomes.
  • Senior Associate candidates should partner effectively across global, regional, and local teams and build collaborative relationships for cross-functional execution.
  • Senior Associate candidates should leverage approved artificial intelligence-enabled tools to enhance productivity, streamline processes, improve deliverable quality, and support data-driven decisions, while using artificial intelligence responsibly and critically evaluating generated outputs.
Responsibilities
  • Provide operational regulatory support for designated countries, clusters, and regions.
  • Support submission logistics and technical aspects to develop and deliver cross-regional, regional, and national regulatory dossiers for initial applications and lifecycle updates, ensuring regulatory compliance throughout the submission process.
  • Partner with Country Regulatory Strategists, International Labeling and Artwork, and other stakeholders to enable timely, high-quality submissions and sustained compliance.
  • Plan regulatory submission timelines and ensure regulatory systems are up to date.
  • Author, deliver, and coordinate local, submission-ready Module 1 dossier components, excluding labeling and artwork components.
  • Author responses to simple local Health Authority queries.
  • Escalate submission-plan delays promptly and develop mitigation strategies aligned with assessed impact and associated risks.
  • Quality-review and approve dossier structures for applicable submissions when required.
  • Support country regulatory teams with tenders, out-of-stock reporting, Annual Product Quality Reviews, risk minimization plans, and regulatory input for launch planning.
  • Identify opportunities to streamline the end-to-end regulatory process using digital tools where applicable.
  • Manage and coordinate lower-complexity regulatory activities for assigned products and dossier execution workflows as appropriate.
  • Deliver designated tasks with quality and timeliness in accordance with applicable policies, standard operating procedures, work instructions, guidelines, and service-level agreements.
  • Author, review, and maintain local regulatory documents and Module 1 dossier components for assigned submission categories, markets, or products.
  • Coordinate receipt of components, translation management, dossier compilation, local ancillary legalization, and submission readiness for timely Health Authority submissions.
  • Monitor regulatory submissions and dossier components against milestones to meet business-critical timelines and regulatory requirements.
  • Support tenders, out-of-stock reporting, Annual Product Quality Reviews, local audit readiness, risk minimization activities, Dear Healthcare Professional Communications, medical information request responses, and other regulatory operational activities.
  • Partner with cross-functional stakeholders and third-party partners to deliver regulatory priorities and operational plans.
  • Escalate and communicate issues affecting submission timelines, quality, compliance, or business commitments, including identifying and escalating Quality Events affecting the role's processes, deliverables, or areas of responsibility.
  • Maintain required training curricula and continued proficiency in regulatory processes, submission requirements, tools, and systems.
  • Support continuous improvement initiatives and contribute to projects that enhance regulatory operational excellence, scalability, efficiency, and compliance.
  • Serve as a subject matter expert for assigned processes, products, regions, or regulatory operational activities, as appropriate.
  • Lead and coordinate lower- to medium-complexity regulatory activities for assigned products and dossier execution workflows as appropriate.
  • Coordinate with relevant subject matter experts and functions to address more complex Health Authority queries based on the Country Regulatory Strategist's query-response strategy.
  • Lead project management for regulatory submissions, including developing timelines, work plans, deliverables, risk assessments, and mitigation strategies.
  • Monitor submission progress and proactively identify, escalate, and resolve issues affecting quality, compliance, resource requirements, or regulatory timelines; support Corrective and Preventive Actions for relevant Quality Events.
  • Represent regulatory operations in project meetings, advocate realistic deliverables, communicate risks, and provide submission-status updates.
  • Contribute to forecasting and resource-planning activities, supporting flexible resourcing and global workload sharing to optimize delivery of regulatory commitments.
  • Identify, evaluate, and implement improvements to submission processes, regulatory operations workflows, and dossier execution efficiencies at local, regional, and global levels.
  • Drive adoption of standardized document authoring, publishing, document management, and archival processes to improve quality, compliance, and operational effectiveness.
  • Apply advanced regulatory and operational knowledge to deliver business outcomes across complex projects and regulatory initiatives.
  • Balance quality, compliance, risk, and speed in a dynamic regulatory environment using critical thinking and sound judgment.
  • Support discussions for lower- to medium-complexity regulatory projects and ensure alignment of submission strategies across global, regional, and local stakeholders.
  • Promote continuous learning, digital fluency, innovation, collaboration, and operational excellence through digital solutions, proactive problem-solving, and stakeholder engagement.
Desired Qualifications
  • Multilingual skills are desirable, including Portuguese for the Latin America EH.
  • Familiarity with pharmaceutical organizational structures, systems, and culture is preferred.
  • An understanding of country and cluster regulatory requirements and trends is preferred.
  • Relevant experience in pharmaceutical regulatory, quality, or compliance fields is preferred.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.

Yahoo Finance
Oct 13th, 2026
Six high-yield dividend stocks fail the payout test, from Ford to Whirlpool's 9.37% mirage

High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.